Acadia Pharmaceuticals Inc. (ACAD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.90 (+5.52%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Acadia Pharmaceuticals Inc. (ACAD)
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Key Insights

Critical company metrics and information

  • Share Price

    $17.17

  • Market Cap

    $2.86 Billion

  • Total Outstanding Shares

    166.39 Million Shares

  • Total Employees

    620

  • Dividend

    No dividend

  • IPO Date

    May 27, 2004

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.acadia.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$10.31 Million
Net Cash Flow From Investing Activities, Continuing$-153.03 Million
Net Cash Flow From Investing Activities$-153.03 Million
Net Cash Flow From Operating Activities, Continuing$202.73 Million
Net Cash Flow, Continuing$60.00 Million
Net Cash Flow From Operating Activities$202.73 Million
Net Cash Flow From Financing Activities$10.31 Million
Net Cash Flow$60.00 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Diluted Earnings Per Share$0.78
Income/Loss From Continuing Operations Before Tax$328.03 Million
Net Income/Loss Available To Common Stockholders, Basic$128.51 Million
Basic Average Shares$2.12 Million
Revenues$929.24 Million
Net Income/Loss Attributable To Parent$128.51 Million
Net Income/Loss$128.51 Million
Diluted Average Shares$2.81 Million
Basic Earnings Per Share$0.78
Income/Loss From Continuing Operations After Tax$128.51 Million
Income Tax Expense/Benefit$8.19 Million
Preferred Stock Dividends And Other Adjustments$0.00
Gross Profit$851.31 Million
Benefits Costs and Expenses$601.21 Million
Operating Income/Loss$112.23 Million
Operating Expenses$739.07 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Cost Of Revenue$77.93 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Research and Development$269.26 Million
Selling, General, and Administrative Expenses$469.81 Million
Costs And Expenses$620.90 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$788.28 Million
Prepaid Expenses$51.55 Million
Equity$577.18 Million
Inventory$86.74 Million
Wages$37.02 Million
Equity Attributable To Parent$577.18 Million
Noncurrent Liabilities$55.74 Million
Assets$976.87 Million
Equity Attributable To Noncontrolling Interest$0.00
Accounts Payable$19.08 Million
Noncurrent Assets$188.58 Million
Liabilities And Equity$976.87 Million
Other Current Liabilities$287.84 Million
Fixed Assets$3.99 Million
Current Liabilities$343.94 Million
Other Current Assets$649.99 Million
Liabilities$399.69 Million
Other Non-current Assets$184.60 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.